1. Market Research
  2. > Pharmaceutical
  3. > Drug Development Market Trends
North America Drug Modelling Software Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By roduct Type ; Application, and Country

North America Drug Modelling Software Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By roduct Type ; Application, and Country

  • September 2020
  • 99 pages
  • ID: 5978895
  • Format: PDF
  • The Insight Partners

Summary

Table of Contents

Search Inside

The North America drug modelling software market is expected to reach US$ 4,588.87 million by 2027 from US$ 2,468.17 million in 2019. The market is estimated to grow at a CAGR of 8.4% during 2020-2027.

The drug modelling software market is growing primarily due to increasing adoption of in-silico modelling tools in drug discovery and rising economic burden of drug discovery in North America.Additionally, growing adoption of artificial intelligence in drug discovery and strategic activities by market players are likely to fuel the growth of the drug modelling software market during the forecast period.

However, factors such as lack of data standardization are likely to restrain the growth of the market.

Drug modelling has become an essential tool in the drug design process.Software-based drug discovery and development methods are playing a key role in the development of novel drugs.

Software-based methods, such structure-based virtual screening, structure-based drug design, as molecular modelling, ligand interaction, and molecular dynamics, are considered to be a powerful tool for investigation of pharmacodynamic and pharmacokinetic properties of drugs.These methods are fast and accurate.

They provide valuable insights of experimental findings and mechanisms of action. In addition, appropriate implementation of these techniques may help in reducing cost of drug designing and development.

Traditional drug discovery and development method is capital-intensive and time-consuming.Moreover, it has high failure rates.

It involves experimental screening of existing libraries of molecules followed by many rounds of chemical synthesis.The process of drug development, from the discovery of a lead compound to its commercial launch, is estimated to take around 10-15 years along with the investment of a huge amount of money.

As per the Pharmaceutical Research and Manufacturers of America, the average cost to research and develop a successful drug is estimated to be US$ 2.6 billion. Moreover, only a small proportion of leads that are selected for further investigation during the initial stages of research are translated into clinical research studies. Over a period, the complexities of drug discovery have increased owing to the increasing size of biologics. As a result, there has been a direct rise in R&D expenditure in the pharmaceutical sector. As per the Pharmaceutical Research and Manufacturers of America, in 2017, biopharmaceutical companies sponsored more than 4,500 clinical trials in the US. These trials accounted for approximately US$ 43 billion; moreover, in 2017, biopharmaceutical companies in the US invested around US$ 97 billion in R&D. At present, the pharmaceutical industry is under tremendous pressure to cope with rising capital requirements in drug discovery research and avoid losses due to drug failure.

In the past few years, several computational tools have been developed for the identification, selection, and optimization of pharmacological lead candidates.Currently, there are several computational approaches available for the drug discovery process.

The predictive power of these tools has been proven to be very advantageous, allowing researchers to bypass the screening of billions of molecules.As a result, computational services, such as quantitative structure-activity relationship (QSAR), modelling, and computer-aided drug design (CADD), have now become an integral part of the pharmaceutical industry.

Moreover, pharmaceutical companies that are focused on the development of large molecules are likely to continue outsourcing their respective drug discovery and development operations from drug modelling providers.

Drugs are essential to curb COVID-19; more than 206,000 people have tragically died from the disease. In the U.S., to give the drug modelling technology a push, ImmunityBio and Microsoft collaborated to support for the research. Supporting COVID-19 vaccine and drug development is the main aim of ImmunityBio’s collaboration with Microsoft to leverage the latter’s Azure platform to create a 3D model of SARS-CoV-2’s spike protein. Additionally, Research projects and innovations related to COVID-19 have ramped up quickly across the University of Michigan, spurred by doctors, public health experts, scientists, economists, and engineers; and encouraged by research leaders. With the emerging outbreak of the COVID-19 pandemic, the drug modelling market is likely to be positively impacted.

In 2019, the software segment based on product type accounted for the highest share of the market.Also, the same segment is estimated to grow at the highest CAGR during the forecast period.

Growth of this segment can be attributed to rise in demand for effective therapeutics and increase in drug discovery efforts of various biologics across a wide range of therapeutics. In addition, strategic activities by service providers, such as collaborations, product advancement, and product launch, in order to accelerate drug discovery timeline are further accelerating the growth of the market.

A few of the major secondary sources associated with the North America drug modelling software market report include World Health Organization (WHO), OECD Health Statistics 2015, Pharmaceutical Research and Manufacturers of America, and Centers of Disease Control and Prevention (CDC).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Tissue Banking Market - Growth, Trends, and Forecasts (2020 - 2025)

  • $ 4250
  • January 2021
  • 114 pages

Certain factors that are driving the market growth include rising healthcare expenditure, growing burden of chronic diseases and advances in drug discovery and development. The burden of chronic diseases ...

  • World
  • Europe
  • Healthcare
  • Tissue Banking
  • Industry analysis
  • Cancer Incidence
  • Health Expenditure

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on